As reported last week in The New York Times, the Accreditation Council for Continuing Medical Education is reviewing policies concerning the council's efforts to keep pharmaceutical industry bias out of the continuing medical education coursework required of doctors. Dr. Murray Kopelow, chief executive of the ACCME, told the Times that the organization intended to publish a list of classes and companies that violated the organization's rules against commercial bias. The exact timing and nature of that action currently is under consideration by the board of directors, according to the ACCME. Also under review is a proposal that CME providers must notify doctors and provide corrective materials when it is determined that any class material was biased in favor of a drug firm. The board's review of these policies is happening concurrently with mounting government pressure to curb commercial bias, as well as scrutiny of whether the pharmaceutical industry will continue to sponsor medical education to the extent it has in the past.